Verisante Technology Inc. V.VRS

RE:RE:RE:RE:RE:RE:Relationship with J&J

[life_of_dan]

July 3, 2015 at 8:32 am VANCOUVER, BRITISH COLUMBIA - Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF) (the Company or Verisante), a leader in skin cancer detection technology, provides a mid-year operational update. Verisante is pleased to announce that the Company has received a purchase order from the Nova Scotia Health Authority for an Aura, which will be used by Dalhousie University in a research study. The Company expects to coordinate delivery and training of the device this year. The Company also continues to receive specialized interest for its VRS Raman Research System, completing a sale to researchers in the division of Johnson & Johnson Skin Care who will be using the device to gather in vivo Raman measurements of lotions applied to the skin. These recent sales follow upon Verisantes exhibit of Aura at the World Congress of Dermatology held in Vancouver, BC, from June 8-13, 2015 where Aura was well received by both the local and international skin specialist community. The Company also took the opportunity to begin a new pilot partnership program with local, Vancouver area doctors to place Auras in high traffic clinics. In addition to the abovementioned developments with Aura and the VRS research system, the Company also continues to make progress with applications for Verisantes Core system for the detection of internal cancers. Earlier in 2015, the Company announced an exciting collaboration between Verisante, the BC Cancer Agency and Imperial College Healthcare NHS Trust to develop an application that would use Verisantes Core laser raman system in a study to determine if the system is able to assist in ascertaining the margins between tumour and normal brain tissue. The initial results have been very encouraging as the study continues to enroll new patients. The study is being led by Dr. Babar Vaqas, a Neurosurgeon and the Principal Investigator. Verisante also continues it associations with world class institutions by expanding its collaboration with Fujian Normal University in China, whereby Verisante is providing two Raman spectrometers to test a new endoscopic probe design which could decrease the manufacturing cost of the Core system by up to 50%.